The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs.
Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.
Vinge has assisted Stendörren Fastigheter AB (publ) (“Stendörren”) in connection with EQT Real Estate II’s, through Chicago Holding AB (“Chicago Holding”), cash offer to the shareholders in Stendörren.
The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs.
Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53.
Vinge has advised Swedavia Real Estate AB’s and Alecta pensionsförsäkring ömsesidigt’s jointly-owned joint venture company Swedish Airport Infrastructure KB and its subsidiary in connection with a restructuring of the group and a SEK 3.7 billion refinancing.
Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.
Vinge has assisted Vostok New Ventures Ltd (“Vostok”) in connection with an investment by a number of investors in Voi Technology AB, a company that provides an electric scooter sharing service.
Vinge has advised the newly-formed company Gotoga, where the ownership structure consists of the existing majority owner in Whyred, in conjunction with its acquisition of the Swedish parent company Hope
